Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice
Roland Rabl, C. Breitschaedel, Stefanie Flunkert, et al.
BMC Neuroscience (2017) Vol. 18, Iss. 1
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

CD4 + T cells contribute to neurodegeneration in Lewy body dementia
David Gate, Emma Tapp, Olivia Leventhal, et al.
Science (2021) Vol. 374, Iss. 6569, pp. 868-874
Open Access | Times Cited: 155
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease
D. L. Price, Maya A. Koike, Asma Khan, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 138
Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease
Takuya Uehara, Chi‐Jing Choong, Masayuki Nakamori, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 87
Neuroinflammation is associated with infiltration of T cells in Lewy body disease and α-synuclein transgenic models
Michiyo Iba, Changyoun Kim, Michelle A. Sallin, et al.
Journal of Neuroinflammation (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 83
A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn (“line 61”) Mice
Franziska Richter, Miloš Stanojlović, Christopher Käufer, et al.
Neurotherapeutics (2023) Vol. 20, Iss. 1, pp. 97-116
Open Access | Times Cited: 22
The hidden side of Parkinson’s disease: Studying pain, anxiety and depression in animal models
Fanny Faivre, Anil Joshi, Erwan Bézard, et al.
Neuroscience & Biobehavioral Reviews (2018) Vol. 96, pp. 335-352
Open Access | Times Cited: 62
A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein
Franziska Richter, Sudhakar R. Subramaniam, Iddo Magen, et al.
Neurotherapeutics (2017) Vol. 14, Iss. 4, pp. 1107-1119
Open Access | Times Cited: 53
Neurofilament-Light Chain as Biomarker of Neurodegenerative and Rare Diseases With High Translational Value
Tina Loeffler, Irene Schilcher, Stefanie Flunkert, et al.
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 48
In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease
D. L. Price, Asma Khan, Rachel Angers, et al.
npj Parkinson s Disease (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 15
“Cell-addictive” dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway
Yanhui Li, Zixuan Chen, Zhiguo Lü, et al.
Theranostics (2018) Vol. 8, Iss. 19, pp. 5469-5481
Open Access | Times Cited: 43
Deciphering motor dysfunction and microglial activation in mThy1-α-synuclein mice: a comprehensive study of behavioral, gene expression, and methylation changes
Brett A. McGregor, Md. Obayed Raihan, Afrina Brishti, et al.
Frontiers in Molecular Neuroscience (2025) Vol. 18
Open Access
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
Jacqui Nimmo, Harry Smith, Chang Yi Wang, et al.
Acta Neuropathologica (2021) Vol. 143, Iss. 1, pp. 55-73
Open Access | Times Cited: 24
Modeling Parkinson's disease‐related symptoms in alpha‐synuclein overexpressing mice
Agata Aniszewska, Joakim Bergström, Martin Ingelsson, et al.
Brain and Behavior (2022) Vol. 12, Iss. 7
Open Access | Times Cited: 16
In vivo imaging of synaptic density with [11C]UCB-J PET in two mouse models of neurodegenerative disease
Mengfei Xiong, Sahar Roshanbin, Johanna Rokka, et al.
NeuroImage (2021) Vol. 239, pp. 118302-118302
Open Access | Times Cited: 22
How Well Do Rodent Models of Parkinson’s Disease Recapitulate Early Non-Motor Phenotypes? A Systematic Review
Tracy D. Zhang, Scott Kolbe, Leah C. Beauchamp, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3026-3026
Open Access | Times Cited: 15
Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson’s disease
Gabriela Henrı́quez, Mahesh Narayan
Exploration of Neuroprotective Therapy (2023), pp. 207-234
Open Access | Times Cited: 8
Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain
Marion Delenclos, Ayman H. Faroqi, Mei Yue, et al.
Acta Neuropathologica Communications (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 28
Cellular Prion Protein Mediates α‐Synuclein Uptake, Localization, and Toxicity In Vitro and In Vivo
Tobias Thom, Matthias Schmitz, Anna‐Lisa Fischer, et al.
Movement Disorders (2021) Vol. 37, Iss. 1, pp. 39-51
Open Access | Times Cited: 18
Intranasal Exposure to Low-Dose Rotenone Induced Alpha-Synuclein Accumulation and Parkinson’s Like Symptoms Without Loss of Dopaminergic Neurons
Monika Sharma, Jaswinder Kaur, Siddhi Rakshe, et al.
Neurotoxicity Research (2021) Vol. 40, Iss. 1, pp. 215-229
Closed Access | Times Cited: 18
Palmitic Acid-Enriched Diet Increases α-Synuclein and Tyrosine Hydroxylase Expression Levels in the Mouse Brain
Jared Schommer, Gurdeep Marwarha, Kumi Nagamoto‐Combs, et al.
Frontiers in Neuroscience (2018) Vol. 12
Open Access | Times Cited: 21
Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice
Sahar Roshanbin, Agata Aniszewska, Astrid Gumucio, et al.
Neurobiology of Aging (2021) Vol. 101, pp. 207-220
Open Access | Times Cited: 17
Intranasal Rotenone Induces Alpha-Synuclein Accumulation, Neuroinflammation and Dopaminergic Neurodegeneration in Middle-Aged Mice
Monika Sharma, Nishant Sharma, Amit Khairnar
Neurochemical Research (2022) Vol. 48, Iss. 5, pp. 1543-1560
Closed Access | Times Cited: 12
Leukotriene Signaling as a Target in α-Synucleinopathies
Katharina Strempfl, Michael S. Unger, Stefanie Flunkert, et al.
Biomolecules (2022) Vol. 12, Iss. 3, pp. 346-346
Open Access | Times Cited: 10
Hepatic and neuronal phenotype of NPC1−/− mice
Estibaliz Santiago-Mujika, Stefanie Flunkert, Roland Rabl, et al.
Heliyon (2019) Vol. 5, Iss. 3, pp. e01293-e01293
Open Access | Times Cited: 17
A Novel NOX Inhibitor Treatment Attenuates Parkinson’s Disease-Related Pathology in Mouse Models
Anurupa Ghosh, Dinesh Verma, Gabriela M. Cabrera, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4262-4262
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top